Brian N Cherry bought $1000K of Atara Biotherapeutics (ATRA)
Executed Sep 4, disclosed Sep 4, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 4), the stock returned -0.5% (delay-adjusted); from the execution session (Sep 4), -0.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Brian N Cherry (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Atara Biotherapeutics, Inc. (ATRA). Across 1 priced purchase filing, the average 21-session return was -0.5% from execution and -0.5% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of ATRA (104,166 sh × $9.60, as filed), executed Sep 4.
Healthcare · Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the U…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→